Nels P. Bergmark

Ash Access Technology, Inc. develops catheters, antimicrobials, vascular access devices and other catheter-related products and services. Its products include zuragen Injection, zuraprep, centros and pipeline. The firm engages in the development and commercialization of proprietary technologies and devices to treat and prevent the clinical consequences of diseases and disorders related to vascular access. The company was founded by Robert B. Truitt and Stephen R. Ash in 1983 and is headquartered in Lafayette, IN.

HemoCleanse, Inc. develops sorbent-based technologies to remove toxins from blood. It offers HemoCleanse-DT, a sorbent-based centrifuge-like device for liver dialysis and drug overdose detoxification applications; and HemoCleanse-PF, a sorbent-based centrifuge-like device for removing protein-bound toxins from plasma in applications, such as treatment of sepsis and autoimmuned diseases. The firm also provides AmSorb Ammonium sorbent for use in HemoCleanse; as an oral sorbent for urea control in the treatment of patients with renal insufficiency or end stage renal disease; and for ammonium removal in treatment of patients with chronic liver diseases. The company was founded by Stephen R. Ash and Robert B. Truitt in 1989 and is headquartered in Lafayette, IN.

ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA.